Evidence map›Paper›PMID 35650277›Full record

ArticleBritish journal of cancer2022

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.

Nicola C Venn, Libby Huang, Lenka Hovorková, Walter Muskovic, Marie Wong, Tamara Law, Susan L Heatley, Seong Lin Khaw, Tom Revesz, Luciano Dalla Pozza and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. CML-like biology:Haematologica · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Biomedicines · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 3 countries.

Nicola C VennMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.
Libby HuangMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.
Lenka HovorkováDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Walter MuskovicMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.
Marie WongComputational Biology, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.
Tamara LawMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.
Susan L HeatleyPrecision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0001-7497-6477
Seong Lin KhawChildren's Cancer Centre, The Royal Children's Hospital, Melbourne, VIC, Australia.
Tom ReveszSchool of Medicine, University of Adelaide, Adelaide, SA, Australia.
Luciano Dalla PozzaCancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Peter J ShawCancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Chris FraserBlood and Bone Marrow Transplant Program, Queensland Children's Hospital, Brisbane, QLD, Australia.
Andrew S MoorePaediatric Oncology, Queensland Children's Hospital, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0001-8062-1779
Siobhan CrossChildren's Haematology/Oncology Centre Christchurch Hospital, Christchurch, New Zealand.ORCID http://orcid.org/0000-0002-3103-9763
Katerina BendakMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.
Murray D NorrisMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-0632-4589
Michelle J HendersonMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-2741-3852
Deborah L WhitePrecision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0003-4844-333X
Mark J CowleyComputational Biology, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-9519-5714
Toby N TrahairMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-3295-228X
Jan ZunaDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Rosemary SuttonMolecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia. rsutton@ccia.unsw.edu.au.ORCID http://orcid.org/0000-0002-0188-6005
Cancer Institute of New South Wales · AUCharles University · CZChildren's Health Queensland Hospital and Health Service · AUChildren's Hospital at Westmead · AUSouth Australian Health and Medical Research Institute · AUChristchurch Hospital · NZRoyal Children's Hospital · AUWomen's and Children's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundABL-class fusions including NUP214-ABL1 and EBF1-PDGFRB occur in high risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to BCR-ABL-positive ALL. Our aim was to evaluate new DNA-based measurable residual disease (MRD) tests detecting these fusions and IKZF1-deletions in comparison with conventional immunoglobulin/T-cell receptor (Ig/TCR) markers.

methodsPrecise genomic breakpoints were defined from targeted or whole genome next generation sequencing for ABL-fusions and BCR-ABL1. Quantitative PCR assays were designed and used to re-measure MRD in remission bone marrow samples previously tested using Ig/TCR markers. All MRD testing complied with EuroMRD guidelines.

resultsABL-class patients had 46% 5year event-free survival and 79% 5year overall survival. All had sensitive fusion tests giving high concordance between Ig/TCR and ABL-class fusion results (21 patients, n = 257 samples, r2 = 0.9786, P < 0.0001) and Ig/TCR and IKZF1-deletion results (9 patients, n = 143 samples, r2 = 0.9661, P < 0.0001). In contrast, in BCR-ABL1 patients, Ig/TCR and BCR-ABL1 tests were discordant in 32% (40 patients, n = 346 samples, r2 = 0.4703, P < 0.0001) and IKZF1-deletion results were closer to Ig/TCR (25 patients, n = 176, r2 = 0.8631, P < 0.0001).

conclusionsMRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for IKZF1-deletions is feasible and provides good alternatives to Ig/TCR tests to monitor MRD in ABL-class ALL.

Indexed as

Fusion Proteins, bcr-ablPrecursor Cell Lymphoblastic Leukemia-LymphomaChildHumansImmunoglobulinsNeoplasm, ResidualReceptors, Antigen, T-CellFusion Proteins, bcr-ablImmunoglobulinsReceptors, Antigen, T-Cell

Identifiers

PMID35650277
PMCPMC9427854
OpenAlexW4281997858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.